Oryzon Genomics
Oryzon Genomics S.A. is a clinical-stage biopharmaceutical company based in Cornellà de Llobregat, Spain, specializing in the discovery and development of epigenetics-based therapeutics aimed at treating oncological and central nervous system (CNS) disorders. The company is recognized as a leader in this field, focusing on personalized medicine approaches. Its key clinical candidates include iadademstat, a selective LSD1 inhibitor currently in Phase II trials for oncology, and vafidemstat, a CNS-optimized LSD1 inhibitor undergoing Phase II trials for CNS and psychiatric diseases. Additionally, Oryzon is developing ORY-3001, another LSD1 inhibitor in preclinical stages for non-oncological diseases, along with various other programs at different development stages. Founded in 2000, Oryzon Genomics is committed to advancing therapeutic solutions in the areas of cancer and neurodegenerative diseases.
Crystax Pharmaceuticals is a biopharmaceutical company specializing in structure-based drug discovery. The firm focuses on identifying and developing new lead compounds for therapeutic applications, particularly in cancer treatment. Crystax employs a combination of structural and biophysical techniques, including X-ray crystallography, NMR, fragment screening, and hit optimization through biophysical analysis and computational chemistry. By utilizing these advanced methods, the company aims to accelerate the drug discovery process and deliver higher quality molecules to the market.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.